Cited by 450Diabetes Treatment and ManagementPancreatic function and diabetesAdipokines, Inflammation, and Metabolic Diseases

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects

Vilsbøll, T., Agersø, H., Krarup, T., Holst, J. J.·2003·The Journal of Clinical Endocrinology & Metabolism

DOI 10.1210/jc.2002-021053

Open this paper in CoChat — free account

Abstract

We have previously shown that type 2 diabetic patients have decreased plasma concentrations of glucagon-like peptide 1 (GLP-1) compared with healthy subjects after ingestion of a standard mixed meal. This decrease could be caused by differences in the metabolism of GLP-1. The objective of this study was to examine the pharmacokinetics of GLP-1 in healthy subjects and type 2 diabetic patients after iv bolus doses ranging from 2.5-25 nmol/subject. Bolus injections iv of 2.5, 5, 15, and 25 nmol of GLP-1 and a meal test were performed in six type 2 diabetic patients [age, mean (range): 56 (48-67) yr; body mass index: 31.2 (27.0-37.7) kg/m(2); fasting plasma glucose: 11.9 (8.3-14.3) mmol/liter; hemoglobin A(1C): 9.6 (7.0-12.5)%]. For comparison, six matched healthy subjects were examined. Peak plasma GLP-1 concentrations increased linearly with increasing doses of GLP-1 and were similar for type 2 diabetic patients and healthy subjects. The peak concentrations of total GLP-1 (C-terminal) after 2.5, 5, 15, and 25 nmol of GLP-1 were 357 +/- 56, 647 +/- 141, 1978 +/- 276, 3435 +/- 331 pmol/liter in the type 2 diabetic patients and 315 +/- 37, 676 +/- 64, 1848 +/- 146, 3168 +/- 358 pmol/liter, respectively, in the healthy subjects (not statistically significant). Peak concentrations of the intact GLP-1 peptide (N-terminal) were: 69 +/- 17, 156 +/- 44, 703 +/- 77, and 1070 +/- 117 pmol/liter in the type 2 diabetic patients and 75 +/- 14, 160 +/- 40, 664 +/- 79, 974 +/- 87 in the healthy subjects (not statistically significant). GLP-1 was eliminated rapidly with clearances of intact GLP-1 after 2.5, 5, 15, and 25 nmol of GLP-1 amounting to: 9.0 +/- 5.0, 8.1 +/- 6.0, 4.0 +/- 1.0, 4.0 +/- 1.0 liter/min in type 2 diabetic patients and 8.4 +/- 4.2, 7.6 +/- 4.5, 5.0 +/- 2.0, 5.0 +/- 1.0 liter/min in healthy subjects. The volume of distribution ranged from 9-26 liters per subject. No significant differences were found between healthy subjects and type 2 diabetic subjects. We conclude that elimination of GLP-1 is the same in obese type 2 diabetic patients and matched healthy subjects. The impaired incretin response seen after ingestion of a standard breakfast meal must therefore be caused by a decreased secretion of GLP-1 in type 2 diabetic patients.

Integrity signals

Registry

Crossref · 10.1210/jc.2002-021053

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citation
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citation
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citation
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916
Self-citation
Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 885
Self-citation
Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Self-citation
Glucagon-Like Peptide-1-(7–36)Amide Is Transformed to Glucagon-Like Peptide-1-(9–36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1
Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Self-citation

Show all 21 references

Sorted by citations

Items 101–200 of 450

The Gut Hormones in Appetite Regulation
Suzuki, K., Jayasena, C. N., & Bloom, S. R. (2011) · Journal of Obesity · doi:10.1155/2011/528401 · Cited by 98
Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide
Kuhre, R. E., Albrechtsen, N. J. W., Hartmann, B., Deacon, C. F., & Holst, J. J. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.12.006 · Cited by 86
Self-citation
Modulation of the Glucagon-Like Peptide-1 Receptor Signaling by Naturally Occurring and Synthetic Flavonoids
Wootten, D. L., Simms, J., Koole, C., Woodman, O. L., Summers, R. J., Christopoulos, A., & Sexton, P. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176362 · Cited by 84
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Carolyn, F. D. (2007) · Frontiers in bioscience · doi:10.2741/2799 · Cited by 83
Design and Synthesis of Conformationally Constrained Glucagon-Like Peptide-1 Derivatives with Increased Plasma Stability and Prolonged in Vivo Activity
Miranda, L. P., Winters, K. A., Gegg, C. V., Patel, A., Aral, J., Long, J., Zhang, J., Diamond, S., Guido, M. V., Stanislaus, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701522b · Cited by 83
Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Candeias, E. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 86
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Self-citation
Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor
Willard, F. S., & Sloop, K. W. (2012) · Experimental Diabetes Research · doi:10.1155/2012/470851 · Cited by 84
Targeting postprandial hyperglycemia
Rendell, M., & Jovanovič, L. (2006) · Metabolism · doi:10.1016/j.metabol.2006.05.012 · Cited by 80
Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease
Pechenov, S., Revell, J. D., Will, S., Naylor, J., Tyagi, P., Patel, C., Liang, L., Tseng, L., Huang, Y., Rosenbaum, A. I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01750-0 · Cited by 84
The gut–brain axis in obesity
Buhmann, H., le Roux, C. W., & Bueter, M. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.003 · Cited by 81
The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period
Sloth, B., Due, A., Larsen, T. M., Holst, J. J., Heding, A., & Astrup, A. V. (2008) · British Journal Of Nutrition · doi:10.1017/s0007114508137710 · Cited by 78
Self-citation
Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies
Wohlfart, P., Linz, W., Hübschle, T., Linz, D., Huber, J., Hess, S., Crowther, D., Ulrich, W., & Ruetten, H. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-84 · Cited by 79
Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
Meier, J. J., & Nauck, M. A. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.007 · Cited by 76
Incretins and other peptides in the treatment of diabetes
Todd, J. F., & Bloom, S. R. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.02071.x · Cited by 76
The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects
Vilsbøll, T., Agersø, H., Lauritsen, T. L. B., Deacon, C. F., Aaboe, K., Madsbad, S., Krarup, T., & Holst, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.07.007 · Cited by 75
Self-citation
Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells
Pala, L., Mannucci, E., Pezzatini, A., Ciani, S., Sardi, J., Raimondi, L., Ognibene, A., Cappadona, A., Vannelli, B., & Rotella, C. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.111 · Cited by 76
Actions of glucagon‐like peptide‐1 receptor ligands in the gut
Holst, J. J., Andersen, D. B., & Grunddal, K. V. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15611 · Cited by 81
Self-citation
Potential of liraglutide in the treatment of patients with type 2 diabetes
Deacon, C. F. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4039 · Cited by 76
Eleven Amino Acid Glucagon-like Peptide-1 Receptor Agonists with Antidiabetic Activity
Mapelli, C., Natarajan, S., Meyer, J.-P., Bastos, M., Bernatowicz, M. S., Lee, V. G., Pluščec, J., Riexinger, D., Sieber-McMaster, E. S., Constantine, K. L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900752a · Cited by 74
The effect of DPP‐4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose
Bock, G., Man, C. D., Micheletto, F., Basu, R., Giesler, P. D., Laugen, J. M., Deacon, C. F., Holst, J. J., TOFFOLO, G. M., Cobelli, C., et al. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03764.x · Cited by 71
Self-citation
Oral delivery of diabetes peptides — Comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context
Reddy, L. H., Urmann, M., Besenius, M., Ulrich, W., Haack, T., Brun, P., Alié, J., Illel, B., Hortala, L., Vogel, R., et al. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.011 · Cited by 72
Incretin Mimetics as Emerging Treatments for Type 2 Diabetes
Joy, S. V., Rodgers, P. T., & Scates, A. C. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e245 · Cited by 72
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118)
Kim, Y. B., Kopcho, L. M., Kirby, M., Hamann, L. G., Weigelt, C. A., Metzler, W. J., & Marcinkeviciene, J. A. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2005.11.010 · Cited by 69
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction
Russell, S. (2012) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-012-9729-9 · Cited by 68
Liraglutide – overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes
Davies, M. J., Kela, R., & Khunti, K. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01330.x · Cited by 66
Impaired Secretion of Total Glucagon-like Peptide-1 in People with Impaired Fasting Glucose Combined Impaired Glucose Tolerance
Zhang, F., Tang, X., Cao, H., Lü, Q., Li, N., Liu, Y., Zhang, X., Zhang, Y., Cao, M., Wan, J., et al. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.4128 · Cited by 67
DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes
Bugliani, M., Syed, F., de Paula, F. M. M., Omar, B. A., Suleiman, M., Mossuto, S., Grano, F., Cardarelli, F., Boggi, U., Vistoli, F., et al. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.01.019 · Cited by 64
Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus
Briones, M., & Bajaj, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1055 · Cited by 63
Liraglutide
Croom, K. F., & McCormack, P. L. (2009) · Drugs · doi:10.2165/11201060-000000000-00000 · Cited by 64
Controlled release of biologics for the treatment of type 2 diabetes
Gilroy, C. A., Luginbuhl, K. M., & Chilkoti, A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.002 · Cited by 64
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes
Mikhail, N. E. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.845 · Cited by 63
In vivo and in vitro degradation of peptide YY3–36 to inactive peptide YY3–34 in humans
Toräng, S., Bojsen-Møller, K. N., Svane, M. S., Hartmann, B., ROSENKILDE, M. M., Madsbad, S., & Holst, J. J. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00394.2015 · Cited by 60
Self-citation
Preparation, Characterization, and Application of Biotinylated and Biotin−PEGylated Glucagon-Like Peptide-1 Analogues for Enhanced Oral Delivery
Chae, S. Y., Jin, C., Shin, H. J., Youn, Y. S., Lee, S., & Lee, K. C. (2007) · Bioconjugate Chemistry · doi:10.1021/bc700292v · Cited by 59
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
Wang, A., Dorso, C. R., Kopcho, L. M., Locke, G. A., Langish, R. A., Harstad, E. B., Shipkova, P. A., Marcinkeviciene, J. A., Hamann, L. G., & Kirby, M. (2012) · BMC Pharmacology · doi:10.1186/1471-2210-12-2 · Cited by 59
Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty
Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Wettergren, A., Svendsen, L. B., Meisner, S., Hovendal, C. P., Knop, F. K., Vilsbøll, T., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0264 · Cited by 59
Self-citation
Incretins
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 60
Four weeks of near‐normalization of blood glucose has no effect on postprandial GLP‐1 and GIP secretion, but augments pancreatic B‐cell responsiveness to a meal in patients with Type 2 diabetes
Højberg, P. V., Vilsbøll, T., Zander, M., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02579.x · Cited by 56
Self-citation
The effect of liraglutide on endothelial function in patients with type 2 diabetes
Nandy, D. K., Johnson, C., Basu, R., Joyner, M. J., Brett, J., Svendsen, C. B., & Basu, A. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114547358 · Cited by 56
Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Kielgast, U. L., Holst, J. J., & Madsbad, S. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804413 · Cited by 56
Self-citation
Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
Skow, M., Bergmann, N. C., & Knop, F. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12685 · Cited by 57
Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice
Zhang, F., Chen, Z., Wu, D., Tian, L., Chen, Q., Ye, Y., Chen, W., Wu, X., Wu, P., Yuan, W., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103382 · Cited by 54
Glucagon and Glucagon-Like Peptides 1 and 2
Holst, J. J. (2009) · Results and problems in cell differentiation · doi:10.1007/400_2009_35 · Cited by 53
Self-citation
Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1
Wang, X., Liu, H., Chen, J., Li, Y., & Qu, S. (2015) · International Journal of Endocrinology · doi:10.1155/2015/651757 · Cited by 57
Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once‐Daily Human GLP‐1 Analog for Treatment of Type 2 Diabetes
Chatterjee, D. J., Khutoryansky, N., Zdravkovic, M., Sprenger, C. R., & Litwin, J. S. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009339189 · Cited by 54
Physiology of the Incretin Hormones, GIP and GLP ‐1—Regulation of Release and Posttranslational Modifications
Holst, J. J., Albrechtsen, N. J. W., ROSENKILDE, M. M., & Deacon, C. F. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180013 · Cited by 72
Self-citation
Population Pharmacokinetics of Liraglutide, a Once‐Daily Human Glucagon‐Like Peptide‐1 Analog, in Healthy Volunteers and Subjects With Type 2 Diabetes, and Comparison to Twice‐Daily Exenatide
Watson, E., Jonker, D. M., Jacobsen, L. V., & Ingwersen, S. H. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009354996 · Cited by 53
Oleoylethanolamide: A fat ally in the fight against obesity
Brown, J. D., Azari, E. K., & Ayala, J. E. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.02.034 · Cited by 56
Synthesis and evaluation of [18F]exendin (9–39) as a potential biomarker to measure pancreatic β-cell mass
Wang, Y., Lim, K., Normandin, M. D., Zhao, X., Cline, G. W., & Ding, Y. (2011) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2011.07.011 · Cited by 52
Incretins, diabetes, and bariatric surgery: a review
Fetner, R., McGinty, J., Russell, C. D., Pi-Sunyer, X., & Laferrère, B. (2005) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2005.09.001 · Cited by 52
The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9–36)a in an isolated rat heart
Ossum, A. M., van Deurs, U., Engstrøm, T., Jensen, J. S., & Treiman, M. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.06.004 · Cited by 51
Hyperglycemia Acutely Lowers the Postprandial Excursions of Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide in Humans
Vollmer, K., Gardiwal, H., Menge, B. A., Goetze, O., Deacon, C. F., Schmidt, W. E., Holst, J. J., & Meier, J. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2197 · Cited by 52
Self-citation
Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects
Drab, S. R. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.609 · Cited by 51
GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety
O’Connor‐Semmes, R., Lin, J., Hodge, R. J., Andrews, S. M., Chism, J. P., Choudhury, A., & Nunez, D. J. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.187 · Cited by 53
Neurobehavioral effects of liraglutide and sitagliptin in experimental models
Kamble, M., Gupta, R., Rehan, H. S., & Gupta, L. K. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.02.003 · Cited by 51
Incretin-based therapies: mimetics versus protease inhibitors
Brubaker, P. L. (2007) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2007.06.005 · Cited by 49
Liraglutide: clinical pharmacology and considerations for therapy
Sisson, E. M. (2011) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.9.896 · Cited by 49
Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs
Nalin, L., Selvaraju, R. K., Velikyan, I., Berglund, M., Andréasson, S., Wikstrand, A., Rydén, A., Lubberink, M., KANDEEL, F. R., Nyman, G. C., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2745-3 · Cited by 48
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47
GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
Menghini, R., Casagrande, V., Rizza, S., & Federici, M. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02124-w · Cited by 50
The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus
Lastya, A., Saraswati, M. R., & Suastika, K. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-849 · Cited by 50
Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis
Dong, C. X., & Brubaker, P. L. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.185 · Cited by 45
Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
Cho, Y. M., Wideman, R. D., & Kieffer, T. J. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.4.262 · Cited by 47
Liposomal formulations of glucagon-like peptide-1: Improved bioavailability and anti-diabetic effect
Hanato, J., Kuriyama, K., Mizumoto, T., Debari, K., Hatanaka, J., Onoue, S., & Yamada, S. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.08.013 · Cited by 45
Novel Pharmacologic Agents for Type 2 Diabetes
Uwaifo, G. I., & Ratner, R. E. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.11.006 · Cited by 45
Is there a place for incretin therapies in obesity and prediabetes?
Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 44
Self-citation
A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists
Hu, E.-H., Tsai, M.-L., Lin, Y., Chou, T.-S., & Chen, T.-H. (2024) · Medicina · doi:10.3390/medicina60030357 · Cited by 43
The molecular basis for the prolonged blood circulation of lipidated incretin peptides: Peptide oligomerization or binding to serum albumin?
Wang, Y., Lomakin, A., Kanai, S., Alex, R., Belli, S., Donzelli, M., & Benedek, G. B. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.035 · Cited by 43
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease
Idorn, T., Knop, F. K., Jørgensen, M. B., Christensen, M., Holst, J. J., Hornum, M., & Feldt‐Rasmussen, B. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3809 · Cited by 41
Self-citation
DPP IV inhibitors: Successes, failures and future prospects
Kshirsagar, A. D., Aggarwal, A. S., Harle, U. N., & Deshpande, A. D. (2011) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2012.02.017 · Cited by 41
Relationship between GLP‐1 levels and dipeptidyl peptidase‐4 activity in different glucose tolerance conditions
Pala, L., Ciani, S., Dicembrini, I., Bardini, G., Cresci, B., Pezzatini, A., Giannini, S., Mannucci, E., & Rotella, C. M. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03010.x · Cited by 40
Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans
Furuta, S., Smart, C., Hackett, A., Benning, R. K., & Warrington, S. (2012) · Xenobiotica · doi:10.3109/00498254.2012.731618 · Cited by 40
The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes
Russell-Jones, D. L. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02465.x · Cited by 40
Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus
Holst, J. J., & McGill, M. A. (2011) · Clinical Drug Investigation · doi:10.2165/11595370-000000000-00000 · Cited by 40
Self-citation
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
Mikhail, N. E. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3374 · Cited by 39
Diabetes: Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus
Campbell, R. K. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h459 · Cited by 39
Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases
Yang, F., Luo, X., Li, J., Yu, L., Zeng, F., Huang, X., Lan, Y., & Liu, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113236 · Cited by 43
Effect of Lipidation on the Structure, Oligomerization, and Aggregation of Glucagon-like Peptide 1
Brichtová, E. P., Edu, I. A., Li, X., Becher, F. J., dos Santos, A. L. G., & Jackson, S. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00484 · Cited by 38
Discovery and characterization of taspoglutide, a novel analogue of human glucagon‐like peptide‐1, engineered for sustained therapeutic activity in type 2 diabetes
Dong, J. Z., Shen, Y., Zhang, J., Tsomaia, N., Mierke, D. F., & Taylor, J. E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01313.x · Cited by 38
Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity
Opinto, G., Natalicchio, A., & Marchetti, P. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.812664 · Cited by 41
Inhibition of human pancreatic and biliary output but not intestinal motility by physiological intraileal lipid loads
Keller, J., Holst, J. J., & Layer, P. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00411.2005 · Cited by 38
Self-citation
Analysis of glucagon-like peptide 1; what to measure?
Heijboer, A. C., Frans, A., Lomecky, M. Z., & Blankenstein, M. A. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.03.010 · Cited by 38
Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents
Li, G., Huan, Y., Yuan, B., Wang, J., Jiang, Q., Lin, Z., Shen, Z., & Huang, H. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.023 · Cited by 38
Population pharmacokinetics of exenatide
Cirincione, B. B., & Mager, D. E. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13135 · Cited by 38
The Identification of Novel Proteins That Interact With the GLP-1 Receptor and Restrain its Activity
Huang, X., Dai, F. F., Gaisano, G., Giglou, K., Han, J., Zhang, M., Kittanakom, S., Wong, V., Li, W., Showalter, A. D., et al. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1047 · Cited by 41
GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation
Movahednasab, M., Dianat‐Moghadam, H., Khodadad, S., Nedaeinia, R., Safabakhsh, S., Ferns, G. A., & Salehi, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01623-w · Cited by 43
Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-Cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes
Akarte, A. S., Srinivasan, B. P., & Gandhi, S. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.03.013 · Cited by 37
Responses of gut and pancreatic hormones, bile acids, and fibroblast growth factor-21 differ to glucose, protein, and fat ingestion after gastric bypass surgery
Jensen, C. Z., Bojsen-Møller, K. N., Svane, M. S., Holst, L. M., Hermansen, K., Hartmann, B., Albrechtsen, N. J. W., Kuhre, R. E., Kristiansen, V. B., Rehfeld, J. F., et al. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00265.2019 · Cited by 37
Self-citation
Lixisenatide, a novel GLP ‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus
Bolli, G. B., & Owens, D. R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12253 · Cited by 37
Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Charbonnel, B. H., & Cariou, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01317.x · Cited by 37
Pharmacokinetics and Pharmacodynamics of Inhaled GLP-1 (MKC253): Proof-of-Concept Studies in Healthy Normal Volunteers and in Patients With Type 2 Diabetes
Marino, M. T., Costello, D. G., Baughman, R., Boss, A., Cassidy, J., D'Amico, C., van Marle, S., van Vliet, A., & Richardson, P. C. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.85 · Cited by 36
On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus.
Vilsbøll, T. (2004) · PubMed · Cited by 36
Self-citation
A Comparative Perspective on Wnt/β-Catenin Signalling in Cell Fate Determination
Garcin, C. L., & Habib, S. J. (2017) · Results and problems in cell differentiation · doi:10.1007/978-3-319-53150-2_15 · Cited by 40
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Hansen, K. B., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02086.x · Cited by 35
Self-citation
Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential
Røder, M. E. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317735283 · Cited by 34
Exendin-4 antagonizes Aβ1-42-induced attenuation of spatial learning and memory ability
Wang, X., Wang, L., Jiang, R., Xu, Y., Zhao, X., & Li, Y. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3742 · Cited by 33
Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog
Edgerton, D. S., Johnson, K., Neal, D. W., Scott, M. F., HOBBS, C. H., Zhang, X., Duttaroy, A., & Cherrington, A. D. (2008) · Diabetes · doi:10.2337/db08-0515 · Cited by 33

Authors: Vilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J.
Affiliations: University of Copenhagen (DK)
Ferring Pharmaceuticals (Denmark) (DK)
Gentofte Hospital (DK)
Corresponding author: Vilsbøll, T.
ORCID: Vilsbøll, T.
Krarup, T.
Holst, J. J.
Venue: The Journal of Clinical Endocrinology & Metabolism
Publisher: The Endocrine Society
Published: 2003-01
Volume: 88
Issue: 1
Pages: 220-224
ISSN: 0021-972X (ISSN-L)
1945-7197
DOI: 10.1210/jc.2002-021053
OpenAlex: W2024409703
Cited by: 444
References: 21
Citations by year: 2026: 10 · 2025: 17 · 2024: 16 · 2023: 13 · 2022: 13 · 2021: 13 · 2020: 5 · 2019: 17 · 2018: 10 · 2017: 16 · 2016: 25 · 2015: 23 · 2014: 22 · 2013: 28 · 2012: 29
FWCI: 10.99
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders: Gentofte Hospital
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords: glucagon-like peptide-1, pharmacokinetics, type 2 diabetes, obesity, elimination rate, intravenous bolus, dose proportionality, healthy subjects comparison, test meal, GLP-1 receptor agonists, GLP-1 analogues, GLP-1 receptor antagonists, GLP-1 receptor signaling
MeSH terms: Aged, Diabetes Mellitus, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Female, Glucagon, Humans, Injections, Intravenous, Male, Middle Aged, Obesity, Osmolar Concentration, Peptide Fragments, Protein Precursors, Reference Values, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks